000289462 001__ 289462
000289462 005__ 20250819132624.0
000289462 0247_ $$2doi$$a10.1016/j.pulmoe.2024.03.003
000289462 0247_ $$2pmid$$apmid:38614857
000289462 0247_ $$2ISSN$$a2531-0429
000289462 0247_ $$2ISSN$$a2531-0437
000289462 0247_ $$2altmetric$$aaltmetric:164748037
000289462 037__ $$aDKFZ-2024-00784
000289462 041__ $$aEnglish
000289462 082__ $$a610
000289462 1001_ $$aSafi, S.$$b0
000289462 245__ $$aLow tumor interleukin-1β expression predicts a limited effect of adjuvant platinum-based chemotherapy for patients with completely resected lung adenocarcinoma: An identification and validation study.
000289462 260__ $$aAmsterdam$$bElsevier$$c2024
000289462 3367_ $$2DRIVER$$aarticle
000289462 3367_ $$2DataCite$$aOutput Types/Journal article
000289462 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726657602_8429
000289462 3367_ $$2BibTeX$$aARTICLE
000289462 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000289462 3367_ $$00$$2EndNote$$aJournal Article
000289462 520__ $$aAdjuvant platinum-based chemotherapy for completely resected non-small cell lung cancer is associated with modest improvement in survival; nevertheless, no validated biomarker exists for predicting the benefit or harm of adjuvant platinum-based chemotherapy.We simultaneously measured 27 cytokines in operative tumor specimens from a discovery cohort (n = 97) by multiplex immunoassay; half of the patients received adjuvant platinum-based chemotherapy, and the other half were observed. We tested possible prognostic and predictive factors in multivariate Cox models for overall survival (OS) and relapse-free survival (RFS), and a tree-based method was applied to detect predictive factors with respect to RFS. The results were validated in an independent validation cohort (n = 93).Fifty-two of 97 (54 %) patients in the discovery cohort and 50 of 93 (54 %) in the validation cohort received adjuvant chemotherapy; forty-four (85 %) patients in the discovery cohort and 37 (74 %) in the validation cohort received four cycles as planned. In patients with low IL-1β-expressing tumors, RFS and OS were worse after adjuvant chemotherapy than after observation. The limited effect of adjuvant chemotherapy for patients with low IL-1β-expressing tumors was confirmed in the validation cohort. Additionally, RFS and OS were prolonged by adjuvant chemotherapy only in patients with high IL-1β-expressing tumors in the validation cohort.This study identified and validated low tumor IL-1β expression as a potential biomarker of a limited response to adjuvant platinum-based chemotherapy after complete resection of pulmonary adenocarcinoma. This finding has the potential to inform adjuvant treatment decisions.
000289462 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000289462 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000289462 650_7 $$2Other$$aBiomarkers
000289462 650_7 $$2Other$$aCytokines
000289462 650_7 $$2Other$$aIL-1β
000289462 650_7 $$2Other$$aLung neoplasms
000289462 650_7 $$2Other$$aTumor microenvironment
000289462 7001_ $$0P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aKrzykalla, J.$$b1$$udkfz
000289462 7001_ $$aHoffmann, H.$$b2
000289462 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, A.$$b3$$udkfz
000289462 7001_ $$aBischoff, H.$$b4
000289462 7001_ $$aEichhorn, M.$$b5
000289462 7001_ $$aKriegsmann, M.$$b6
000289462 7001_ $$aPoschke, I.$$b7
000289462 7001_ $$aStögbauer, F.$$b8
000289462 7001_ $$0P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45$$aUmansky, Ludmila$$b9
000289462 7001_ $$aMogler, C.$$b10
000289462 7001_ $$aWeichert, W.$$b11
000289462 7001_ $$aWinter, H.$$b12
000289462 7001_ $$aBeckhove, P.$$b13
000289462 7001_ $$aMuley, T.$$b14
000289462 773__ $$0PERI:(DE-600)3009651-0$$a10.1016/j.pulmoe.2024.03.003$$gp. S2531043724000436$$pnn$$tPulmonology$$vnn$$x2531-0429$$y2024
000289462 8564_ $$uhttps://inrepo02.dkfz.de/record/289462/files/Low%20tumor%20interleukin-1%20expression%20predicts%20a%20limited%20effect%20of%20adjuvant%20platinum-based%20chemotherapy%20for%20patients%20with%20completely%20resected%20lung%20adeno.pdf
000289462 8564_ $$uhttps://inrepo02.dkfz.de/record/289462/files/Low%20tumor%20interleukin-1%20expression%20predicts%20a%20limited%20effect%20of%20adjuvant%20platinum-based%20chemotherapy%20for%20patients%20with%20completely%20resected%20lung%20adeno.pdf?subformat=pdfa$$xpdfa
000289462 909CO $$ooai:inrepo02.dkfz.de:289462$$pVDB
000289462 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5a7a75d1b29b770f98f1bb2062fc3df9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000289462 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000289462 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000289462 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000289462 9141_ $$y2024
000289462 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPULMONOLOGY : 2022$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-15T16:03:54Z
000289462 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-15T16:03:54Z
000289462 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2022-09-15T16:03:54Z
000289462 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-27
000289462 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bPULMONOLOGY : 2022$$d2023-10-27
000289462 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x0
000289462 9201_ $$0I:(DE-He78)A370-20160331$$kA370$$lKKE Dermatoonkologie$$x1
000289462 980__ $$ajournal
000289462 980__ $$aVDB
000289462 980__ $$aI:(DE-He78)C060-20160331
000289462 980__ $$aI:(DE-He78)A370-20160331
000289462 980__ $$aUNRESTRICTED